Sana Hosni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sana Hosni has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Alajati
Department of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany
27 shared publications - Marieta Toma
Institute of Pathology, University Hospital Bonn, Bonn, Germany
26 shared publications - Michael Hölzel
Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany
26 shared publications - Niklas Klümper
Institute of Experimental Oncology, University Hospital Bonn, Bonn, Germany
26 shared publications - Glen Kristiansen
Institute of Pathology, University Hospital Bonn, Bonn, Germany
14 shared publications - Alexander Semaan
Department of Surgery, University Hospital Bonn, University of Bonn, Bonn, Germany
13 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Parental tumor localization of cholangiocarcinoma (CC) PDO cultures.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Parental tumor localization of cholangiocarcinoma (CC) PDO cultures.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Expression of CK7 and CA19-9 via immunohistochemistry (IHC) in PDO cultures.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Expression of CK7 and CA19-9 via immunohistochemistry (IHC) in PDO cultures.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Complete and incomplete expression patterns of Her2 and Her3 in cholangiocarcinoma.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Complete and incomplete expression patterns of Her2 and Her3 in cholangiocarcinoma.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
TCGA cholangiocarcinoma cohort survival analysis. Overall survival analysis with respect to gene expression of Her2 (ERBB2), Trop2 (TACSTD2), Her3 (ERBB3), folate receptor 1 (FOLR1), and Nectin4 (PVRL4) in TCGA Bile Duct Cancer (CHOL) dataset (36 primary tumor).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
TCGA cholangiocarcinoma cohort survival analysis. Overall survival analysis with respect to gene expression of Her2 (ERBB2), Trop2 (TACSTD2), Her3 (ERBB3), folate receptor 1 (FOLR1), and Nectin4 (PVRL4) in TCGA Bile Duct Cancer (CHOL) dataset (36 primary tumor).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
HER2/HER3 IHC scoring criteria following gastric cancer guidelines. A table listing the definition and interpretation of the HER2 and HER3 IHC scoring system.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
HER2/HER3 IHC scoring criteria following gastric cancer guidelines. A table listing the definition and interpretation of the HER2 and HER3 IHC scoring system.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Intratumoral heterogeneity of Trop2 expression in a cholangiocarcinoma tissue microarray (TMA).
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Intratumoral heterogeneity of Trop2 expression in a cholangiocarcinoma tissue microarray (TMA).
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Organoid culture media protocol.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Organoid culture media protocol.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Clinicopathological data of the patients included in the TMA and PDO cultures.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Clinicopathological data of the patients included in the TMA and PDO cultures.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Trop2 gene expression in cholangiocarcinoma cell lines.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Trop2 gene expression in cholangiocarcinoma cell lines.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Cholangiocarcinoma is a rare and aggressive cancer type with limited therapeutic options. Several novel antibody–drug conjugates (ADC) have demonstrated promising antitumor activity in solid tumors. This study aimed to investigate the expression and the potential prognostic role of the protein targets of the recently developed ADCs in cholangiocarcinoma. Moreover, the study aimed to establish patient-derived tumor organoids (PDO) and to employ them for in vitro ADC testing. We evaluated the expression of TROP2, NECTIN4, folate receptor 1, HER2, and HER3 via IHC in a cholangiocarcinoma tissue microarray (n = 113) and analyzed the expression level with respect to clinicopathologic parameters. Furthermore, we generated cholangiocarcinoma PDO culture lines and used them to test the antitumor activity of ADCs in vitro. IHC analyses revealed that TROP2 was the most frequently expressed (91% of cases), followed by folate receptor 1 (51%), NECTIN4 (49%), HER3 (20%), and HER2 (7%). TROP2 showed moderate to high expression (H-score ≥100) in 74% of cases. No significant correlations with overall or disease-free survival, tumor grade, or tumor stage were observed. Six cholangiocarcinoma PDO lines were successfully established (55% success rate). All PDO lines expressed TROP2 concordantly with their parental tumors and showed growth inhibition (IC50 = 0.1–0.4 μg/mL) in response to sacituzumab govitecan (TROP2-targeting ADC). This study reveals that TROP2 is widely expressed in cholangiocarcinoma. Moreover, it provides preclinical evidence for the potential of the use of sacituzumab govitecan as a novel therapeutic strategy in treating patients with cholangiocarcinoma.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Antibody–Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma
Cholangiocarcinoma is a rare and aggressive cancer type with limited therapeutic options. Several novel antibody–drug conjugates (ADC) have demonstrated promising antitumor activity in solid tumors. This study aimed to investigate the expression and the potential prognostic role of the protein targets of the recently developed ADCs in cholangiocarcinoma. Moreover, the study aimed to establish patient-derived tumor organoids (PDO) and to employ them for in vitro ADC testing. We evaluated the expression of TROP2, NECTIN4, folate receptor 1, HER2, and HER3 via IHC in a cholangiocarcinoma tissue microarray (n = 113) and analyzed the expression level with respect to clinicopathologic parameters. Furthermore, we generated cholangiocarcinoma PDO culture lines and used them to test the antitumor activity of ADCs in vitro. IHC analyses revealed that TROP2 was the most frequently expressed (91% of cases), followed by folate receptor 1 (51%), NECTIN4 (49%), HER3 (20%), and HER2 (7%). TROP2 showed moderate to high expression (H-score ≥100) in 74% of cases. No significant correlations with overall or disease-free survival, tumor grade, or tumor stage were observed. Six cholangiocarcinoma PDO lines were successfully established (55% success rate). All PDO lines expressed TROP2 concordantly with their parental tumors and showed growth inhibition (IC50 = 0.1–0.4 μg/mL) in response to sacituzumab govitecan (TROP2-targeting ADC). This study reveals that TROP2 is widely expressed in cholangiocarcinoma. Moreover, it provides preclinical evidence for the potential of the use of sacituzumab govitecan as a novel therapeutic strategy in treating patients with cholangiocarcinoma.